The University of Texas MD Anderson Cancer Center R9 Head & Neck Facility Refresh - 160165/ME Introduction to MD Anderson MD Anderson is known throughout the world for high-quality cancer care, research, academic programs and prevention services. Since its establishment in 1941, MD Anderson has made major contributions to improve the outlook for cancer patients everywhere. MD Anderson was one of the first three federally designated comprehensive cancer centers by the National Cancer Act of 1971. A survey of health professionals has routinely ranked MD Anderson as one of the two premier cancer centers in the nation for the past eight years. Over 55,000 persons annually seek care at MD Anderson. The team approach to cancer care, pioneered at MD Anderson, has been strengthened by consolidating specialty clinics into multi-disciplinary care centers that allow patients to receive more ambulatory care and treatment in a single location. MD Anderson offers one of the largest bone marrow and stem cell transplantation programs, as well as clinical trials to improve existing therapies. Teams of clinical specialists collaborate with scientists on problems of common interest and test theories that shorten the application of better treatment methods. Translational research studies are responsible for the promising field of chemoprevention, which uses synthetic vitamins to reverse pre-malignant lesions and halt the recurrence of some cancers, and for innovative gene therapy strategies being evaluated for several forms ofcancer. With faculty and staff working in more than 30 buildings in the greater Houston area and in central Texas, MD Anderson is the largest freestanding cancer center in the world. The physical plant covers more than 11 million square feet, featuring the latest equipment and facilities to support growing needs in outpatient and inpatient care, research, prevention and education. It includes inpatient hospital facilities with 571 beds. Construction projects include the addition of 12 floors that can accommodate more than 300 new inpatient beds in Alkek Hospital on the North Campus; two new research buildings on the South Campus that will house the Center for Advanced Biomedical Imaging Research and Center for Targeted Therapy as part of the McCombs Institute; and MD Anderson's first facility on its Mid Campus, a 25-story building to support current office space and future growth needs. In addition to its main campus in the Texas Medical Center and two research campuses in Bastrop County, Texas, MD Anderson has developed a number of local, national and international affiliations RFx Overview PROJECT DESCRIPTION AND SCOPE: This project is located on the 9th floor of the Charles LeMaistre Clinic building. The scope includes the aesthetic renovation of approximately 10,000 sq. ft. of clinic exam, treatment, operatory, and public waiting rooms. New flooring and wall finishes along with new millwork to be scheduled in the renovations with minimal electrical and HVAC scope. Plumbing to include demolition and replacement of fixtures for exam, break and treatment rooms. PRE-SUBMITTAL CONFERENCE: A pre-submittal conference will be held at the time and location described below. DECEMBER 18, 2017 at 8:00 AM, LOCAL TIME The University of Texas MD Anderson Cancer Center FANNIN HOLCOMBE BUILDING 6900 FANNIN STREET CONFERENCE ROOM FHB3.1021 HOUSTON, TEXAS 77030 A guided tour of the project site will not be included as a part of the conference agenda. This will be the only opportunity for Respondents to view the project site before the Submittal Deadline. Attendance at the pre-submittal conference is optional. Questions related to this RFP must be sent via the information request form. All questions must be received no later than December 21, 2017 4:00 PM. Questions received after this time will not be accepted. Questions will not be answered via telephone. All answers to any questions or inquiries will be posted on the webpage for all Suppliers to access. It is the intent of MD Anderson to respond to all questions and concerns; however, MD Anderson shall reserve the right to decline to respond to any question or concern. It is important to note that the supplier or suppliers selected to develop MD Anderson's RFP are not automatically qualified to engage with the Institution for purposes of implementing the recommended strategy or solutions. The engagement of contracted services for implementation can, at MD Anderson's discretion, be solicited via a second and separate Request for Proposal. Standard Riders and Agreements AA RFP.pdf Addendum 1 Sign in Sheet HUB Tip Sheet.pdf Addendum 2 RFI Questions and Answers.pdf Attachment A Draft Agreement and Exhibits.pdf Attachment B HUB Policy Rider 104-C.pdf Attachment C RFI Form.pdf Attachment D Pricing and Delivery Proposal.pdf ***Interested suppliers should also note that Subcontracting Opportunities are probable in connection with this solicitation. Please review the HUB Subcontracting Tip Sheet ***RFx refers to RFP, RFQ, RFI, ITB, etc. Return to Supply Chain Management List of Current Bids.

Bid Protests Not Available